Work

Beyond prostate-specific antigen: ctDNA as an early compass for treatment adaptation in metastatic prostate cancer

Year: 2026

Type: article

Abstract: In a recent study published in Nature Cancer , Jayaram and colleagues 1 demonstrated that persistent circulating tumor DNA detection during first-line intensified therapy independently predicts poor survival in patients with metastatic castration-sensitive prostate cancer, providing prognostic information earlier than prostate-specific antigen (PSA) kinetics. These findings support circulating tumor DNA as a promising dynamic biomarker for early treatment adaptation and highlight its potential to complement PSA in guiding precision therapeutic strategies.

Source: Signal Transduction and Targeted Therapy

DOI: 10.1038/s41392-026-02948-2

Authors: Giandomenico Roviello, Matteo Santoni, Lorenzo Antonuzzo

Institutions: University of Florence, Ospedale di Macerata, ARON Research Foundation ETS, Azienda Ospedaliero-Universitaria Careggi

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,790